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 Pathophysiology of Rosacea 
 Rosacea is a common chronic, often underdiagnosed, 
skin disease of uncertain etiology. The various clinical 
manifestations associated with this disease most fre-
quently occur in the light-skinned Caucasian population, 
and in persons between 30 and 50 years of age  [1, 2] . Un-
til now the conventional wisdom has been that rosacea is 
more common in women than in men  [2] , whereas a re-
cent analysis based on a cross-sectional study of rosacea 
(1995–2002) in 50,235 outpatients indicates that overall 
both sexes are equally affected by the disease  [3] . The der-
matological condition of rosacea mainly affects the cheek, 
nose, chin and central forehead. Furthermore, the dis-
ease may be linked to ocular manifestations  [4] . The ear-
liest symptoms associated with rosacea are intermittent, 
central facial flushing and erythema. More than 90% of 
the patients with rosacea experience flushing with epi-
sodes lasting up to 30 min occurring daily in more than 
60% of the affected individuals  [5–7] . With repetitive cy-
cles, flushing becomes more prominent and facial red-
ness deepens, in the end repeated episodes of facial flush-
ing may cause persistent erythema and telangiectasia  [8] . 
Many patients suffer from a stinging pain associated with 
episodes of flushing which can appear unpredictably or 
in relation to environmental, chemical, food or emotion-
al triggers, especially exposure to sun  [1] .
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 Abstract 
 Until today, the pathogenesis of rosacea is not known in de-
tail. Yet in recent years evidence has been accumulating that 
rosacea with its common symptoms such as inflammatory 
lesions, erythema, telangiectasia, phymatous changes, and 
ocular symptoms is of inflammatory nature. Tetracycline de-
rivatives like doxycycline successfully used in the treatment 
of skin diseases like acne and rosacea seem to inhibit differ-
ent inflammatory pathways involved in the pathogenesis by 
various modes of action. Although data for skin diseases are 
relatively scanty, the following modes of action of tetracy-
clines seem to be most relevant for an effective treatment of 
acne and rosacea: inhibition of matrix metalloproteinases, 
downmodulation of cytokines, inhibition of cell movement 
and proliferation, inhibition of granuloma formation, inhibi-
tion of reactive oxygen species, nitric oxide, and angiogen-
esis, whereas inhibition of phospholipase A2 seems to be of 
lower importance. The role of the saprophytic mite  Demodex 
folliculorum remains to be clarified. Additional studies are 
necessary to further elucidate how tetracyclines work in ro-
sacea treatment.  Copyright © 2009 S. Karger AG, Basel 
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 Until today, the pathogenesis of rosacea is not known 
in detail. Yet in recent years evidence has been accumu-
lating that rosacea is of inflammatory nature even 
though most data have their origin in diseases related to 
rosacea, namely acne vulgaris and, most commonly, 
periodontitis. For example, in biopsies of inflammatory 
lesions from patients with acne an increase in proin-
flammatory cytokines like tumor necrosis factor-  
(TNF-  ) and interleukin-1  (IL-1  ) could be demon-
strated  [9] . These cytokines trigger a chain of reactions, 
such as the release of matrix metalloproteinases (MMPs), 
especially MMP-1, -3 and -9, involved in the degrada-
tion of extracellular matrix and inflammatory damage 
in turn supporting the development of papulopustular 
lesions  [10, 11] . The fact that such lesions occur in rosa-
cea as well supports the thesis of an inflammatory 
pathophysiology of this disease. Anyway, 2 further me-
diators of inflammation, reactive oxygen species (ROS) 
and nitric oxide (NO), have been shown to play a role in 
rosacea pathophysiology  [12, 13] . It has in particular 
been shown that patients with severe rosacea have an 
impaired defense capacity against the proinflammatory 
and damaging effects of ROS  [11, 14] . Reactive nitrogen 
intermediates like NO in turn are responsible for vaso-
dilatation possibly leading to increased vessel permea-
bility and edema and supporting erythema and telangi-
ectasia  [11] . Flushing is caused by increased cutaneous 
blood flow because of capillary dilatations and is be-
lieved to be under vasomotor control  [8] . It seems to 
arise from a dysregulation in the cutaneous vasomotor 
response, which, triggered by neurogenic, hormonal, 
thermal, topical or other stimuli, leads to an abnormal 
and persistent dilatation of blood vessels  [15] . It is worth 
discussing that flushing – at least in the erythematotel-
angiectatic subtype of rosacea – may be due in part to 
an abnormal expression, function, distribution or re-
sponsiveness of   -adrenergic receptors  [15] .
 A possible link between  Helicobacter pylori infections 
and rosacea is discussed in the literature as well  [11] . Sev-
eral authors have also proposed that microscopic sapro-
phytic mites – known as  Demodex folliculorum – play a 
pathogenic role in papulopustular rosacea  [16–21] . Mites 
increased in number may be involved in the pathogenesis 
of rosacea by provoking inflammatory or allergic reac-
tions, by mechanical blockage of follicles or by acting as 
vectors for micro-organisms  [17, 22] . It has been suggest-
ed that a density of  D. folliculorum  1 5/cm 2 as determined 
with the standardized skin surface biopsy could be re-
garded as pathogenic  [18] , but other observations suggest 
that increased density of  D. folliculorum , at least in peri-
oral dermatitis, is a secondary phenomenon, associated 
with previous treatment with topical steroids  [23] .
 Most recently it could be shown that symptoms of ro-
sacea are exacerbated by factors that trigger innate im-
mune responses, such as the release of cathelicidin anti-
microbial peptides. These peptides are produced and se-
creted by keratinocytes  [24] . Clearly, there is a role of 
cathelicidin in skin inflammatory responses  [25] , espe-
cially for cathelicidin LL-37  [24] . Individuals with rosa-
cea express cathelicidin at abnormally high levels in their 
facial skin, and specific proteolytically processed forms 
of cathelicidin peptides found in rosacea differ from 
those in normal individuals  [25] . This means that in the 
pathogenesis of rosacea, cathelicidin peptides are abnor-
mally processed to forms that induce inflammation 
 [26] .
 If changes in the skin pH play a role in pathophysiol-
ogy, as it is reported for several skin diseases like irritant 
contact dermatitis, atopic dermatitis, ichthyosis or acne 
vulgaris  [27] , remains to be clarified.
 In summary, there is good evidence that all the stig-
mata of rosacea are manifestations of an inflammatory 
process. It is  highly probable that inflammatory path-
ways involved in the pathogenesis of this disease con-
comitantly contribute to the common complaints such as 
inflammatory lesions sensu stricto, erythema, telangiec-
tasia, phymatous changes and ocular symptoms  [28] . 
This view is supported by the fact that drugs like doxycy-
cline successfully used in the treatment of rosacea inhib-
it various pathways of inflammation finally leading to an 
improvement of symptoms  [9, 13, 29–31] . Furthermore, 
the anti-inflammatory properties of doxycycline strong-
ly correspond to the pathophysiologic inflammatory 
mechanisms related to rosacea  [31] .
 Tetracyclines and Their Role in the Treatment of 
Rosacea 
 Tetracyclines are broad-spectrum antibiotics that have 
been used in the treatment of rosacea for decades  [9] . 
Treatment of papulopustular rosacea with tetracycline 
requires a 3- or 4-week regimen to achieve substantial 
improvement  [32] . Tetracycline (250–1,000 mg per day), 
doxycycline (100–200 mg per day and – as demonstrated 
recently – also 20–40 mg per day) and minocycline (50–
100 mg per day) are the most commonly applied com-
pounds  [33] . Until recently, the use of oral tetracyclines 
for rosacea was mainly based on clinical experience and 
a limited number of placebo-controlled studies  [9, 34, 35] . 
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However, most recent studies were carried out on the ba-
sis of a sufficiently large number of patients and can 
therefore be considered to be of high quality  [31] .
 Today, the effectiveness of tetracyclines in skin dis-
eases is considered to depend on their nonantibiotic ac-
tions, though originally developed as antibacterial drugs. 
Tetracyclines, besides acting as antibiotics, may also af-
fect inflammation  [31, 36] , cell proliferation  [37] , apopto-
sis  [38, 39] and angiogenesis  [40] by variable mechanisms 
of action. In particular, it is the ability of tetracyclines to 
reduce the inflammatory response that significantly con-
tributes to the clinical effectiveness for various indica-
tions like rosacea  [30] . However, the observation that tet-
racyclines under ex vivo conditions augment the expres-
sion of cyclo-oxygenase-2 and increase prostaglandin E2 
production  [41] is not in line with the data described be-
fore because cyclo-oxygenase-2 and prostaglandin E2 ac-
tivation are known to propagate inflammatory processes 
 [42] .
 Today, second-generation tetracyclines, including mi-
nocycline and especially doxycycline, are most frequent-
ly and most successfully used in the treatment of rosacea. 
In comparison with their parent drug, the new genera-
tion of tetracyclines has an improved bioavailability, a 
longer elimination half-life and can be taken with food 
which minimizes gastrointestinal side effects  [43] . A big 
advantage over the parent drug is that these substances 
are helpful for rosacea patients already at a subantimicro-
bial yet anti-inflammatory dose  [31] . Thus, an effective 
and tolerable long-term therapy is feasible without run-
ning the risk of long-term antibiosis, i.e. undesired ad-
verse effects such as gastrointestinal distress, candidal 
vulvovaginitis and/or the development of antibiotic-re-
sistant micro-organisms  [44] .
 Subantimicrobial-dose doxycycline is the only tetra-
cycline approved in the USA for long-term use for up to 
12 months  [33] . The dosage of 20 mg of doxycycline hy-
clate twice daily or 40 mg once daily has been shown to 
be effective in the treatment of papulopustular rosacea 
with an excellent risk-benefit ratio. It has in particular 
been found that a 40-mg controlled-release formulation 
of doxycyline, applied once daily as Oracea TM , conferred 
peak anti-inflammatory efficacy in the treatment of ro-
sacea  [45] . At subantimicrobial doses, long-term use of 
anti-inflammatory-dose doxycyline might not propagate 
bacterial resistance  [33, 44, 46] . Two phase III, parallel-
group, multicenter, randomized, double-blind, placebo-
controlled studies have in fact further demonstrated the 
efficacy and safety of a 16-week treatment with anti-in-
flammatory doxycycline (40 mg once daily) in patients 
with rosacea  [31] . This medication led to a significant re-
duction in inflammatory lesions  [31] . Hence anti-inflam-
matory doxycycline (40 mg) applied once daily must be 
regarded to be a promising therapy strategy for papulo-
pustular rosacea – besides topical therapies with metro-
nidazole or azelaic acid. However, to our knowledge it is 
not known if tetracyclines, in particular doxycycline, are 
able to improve the symptom flushing, whereas topical 
application of selective   1-adrenergic receptor agonists 
like oxymetazoline seems to be successful in this regard 
 [15] . This finding is in accordance with the belief that 
flushing may be due, at least partly, to an abnormal ex-
pression, function, distribution or responsiveness of   -
adrenergic receptors  [15] .
 Tetracycline Derivatives, Especially Doxycycline, 
and Their Mode of Action 
 Inhibition of MMPs 
 In the 1980s, Golub et al.  [47] discovered a novel non-
antimicrobial property of tetracyclines. They found that 
tetracyclines have the ability to inhibit the activity of in-
terstitial MMPs from a variety of cells like neutrophils 
and macrophages and tissues such as skin  [47, 48] . MMPs 
are zinc-dependent enzymes significantly involved in the 
remodeling of connective tissue. They are secreted by res-
ident and inflammatory cells that collectively degrade 
most of the constituent macromolecules of the extracel-
lular matrix. These enzymes with their subgroups of col-
lagenases (MMP-1, MMP-8, MMP-13) and gelatinases 
(MMP-2, MMP-9) play an important role in many in-
flammatory diseases, wound healing, embryogenesis, tu-
mor invasion and angiogenesis  [30, 49] . Furthermore, 
MMPs contribute to cytokine (i.e. IL-1  )-induced vascu-
lar dysfunction as could be shown in vitro and in an in 
vivo model of acute inflammation  [50] ( fig. 1 ). Later it has 
been observed that tetracycline inhibition of MMPs dif-
fers between species, tissues and even cells from the same 
tissue  [51] . Furthermore, it could be shown that the mem-
bers of the tetracycline family differ in their potency to 
inhibit extracellular collagenase activity, with the semi-
synthetic drugs doxycycline and minocycline being more 
potent than tetracycline itself  [48, 52] .
 In vitro and in vivo studies report that tetracycline 
derivatives are able to inhibit the activity of various 
MMPs playing a role in the breakdown of the extracel-
lular matrix, including MMP-13 (collagenase-3), MMP-8 
(collagenase-2), MMP-1 (collagenase-1), MMP-2 (gela-
tinase A), MMP-9 (gelatinase B) and MMP-12 (macro-
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phage metalloelastase)  [11, 31, 53, 54] . For some MMPs it 
has been shown that, in addition to inhibiting MMP ac-
tivity, tetracycline derivatives like doxycycline may also 
reduce enzyme expression at the transcriptional level 
 [55] .
 While the inhibitory effects of low-dose doxycycline on 
MMPs are described in detail in the context of the man-
agement of periodontitis  [56–60] , available data for skin 
diseases like acne or rosacea are relatively scanty. How-
ever, there are data indicating that MMP-9 can be inhib-
ited by tetracycline derivatives as well probably due to re-
duction in the chemotaxis of neutrophils, which are known 
to store MMP-9  [30] . The inhibitory effect of doxycycline 
on MMP-9 levels could be approved by studies using an 
experimental dry-eye model in mice  [61] . The studies of 
Kim et al.  [62] showing that doxycycline inhibits the TGF-
  1-induced production of MMP-9 in cultured corneal ep-
ithelial cells as well suggest hat this finding might be rel-
evant to the pathogenesis in ocular rosacea  [49, 62] . More 
evidently, recent work even suggests that high levels of 
MMP-8 in the tear fluid are correlated with ocular rosacea 
and that low-dose doxycycline is able to lower the patho-
logically increased levels in these patients. Määtä et al.  [63] 
actually found that the mean MMP-8 concentrations were 
significantly higher in patients with ocular rosacea (157 
  g/ml) than in normal subjects (53   g/ml) but decreased 
to 79 and 53   g/ml in patients with ocular rocacea after 4 
and 8 weeks of treatment with low-dose doxycycline, re-
spectively ( fig. 2 ). The reduction in MMP-8 levels was re-
lated to a relief in the patients’ subjective symptoms  [63] . 
Up to now, doxycycline hyclate is the only drug whose 
properties to inhibit MMPs have sufficed for approval of 
clinical use  [64] , but the exact mode of action on the mo-
lecular level is still unknown. Recent work indicates that 
doxycycline does not directly inhibit MMPs or the synthe-
sis/secretion of these proteases. Though orally adminis-
tered doxycycline caused a disappearance of the MMPs 
indicative of disease progression in patients with superfi-
cial ocular diseases, especially rosacea, no doxycyline 
could be detected in their tear samples  [65] . Thus, doxycy-
cline seems to influence MMPs in an indirect way.
 Inhibition of Phospholipase A2 
 Extracellular phospholipase A2 (PLA2) plays an im-
portant role in articular and extra-articular inflamma-
tory processes  [66] . The tetracyclines minocycline and, to 
a lesser extent, doxycycline have been shown to be in-
hibitory to both pancreatic and nonpancreatic PLA2 in 
vitro  [66] . However, the doxycycline concentration need-
ed for in vitro inhibition of the enzyme activity in serum 
from patients with acute necrotizing pancreatitis is high-
er than that achieved after intravenous injections in clin-
ical use  [67] . Thus, up to now the importance of PLA2 
inhibition by doxycycline in vivo and especially in skin 
diseases like rosacea remains unclear, particularly with 
regard to the finding that in tears of patients with ocular 
rosacea and, more specifically, in patients with dry eyes 
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 Fig. 1. Application of MMP inhibitor doxycycline (30   M ) abol-
ishes the spontaneous loss of phenylepinephrine-induced vascu-
lar tone of rat aortae in vitro. The response of aortic rings taken 
from normal rats to phenylepinephrine is shown. Phenylepineph-
rine was added after 1.5 h of equilibration and then rings were 
treated with doxycycline (30   M ; black circles) or double-distilled 
H 2 O (white circles) vehicle (from Lalu et al.  [50] , with permis-
sion). 
 Fig. 2. Tear fluid MMP-8 concentration in controls, as well as 
ocular rosacea (OCR) patients before treatment and after 4 and 8 
weeks of oral doxycycline regimen. Means  8 SD are presented 
(from Määtä et al.  [63] , with permission). 
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the content of PLA2 of group IIA is significantly lower 
compared to normal controls  [68] .
 Downmodulation of Cytokines 
 Inflammatory lesions from acne patients contain in-
creased levels of proinflammtory cytokines like TNF-  
and IL-1  postulated to be involved in the inflammatory 
cascade of acne  [9] and triggering chemical responses like 
the release of certain MMPs  [13] . There is evidence that 
tetracyclines at subantimicrobial doses reduce inflam-
mation by their downregulating properties  [36] , especial-
ly with respect to TNF-  and IL-1   [69] , IL-8  [70] and 
IL-10  [71] . Furthermore, low-dose doxycycline seems to 
be able to normalize lowered levels of cytokines neces-
sary for repair and regeneration. In patients with severe 
generalized chronic periodontitis, subantimicrobial-
dose doxycycline increases the levels of TGF-  1 in the 
gingival crevicular fluid and by this means contributes to 
the inhibition of connective tissue breakdown  [72] . For 
rosacea no corresponding studies are available so far, but 
it is to be assumed that the described mechanisms are, at 
least partly, transferable to this disease as well.
 Inhibition of Cell Movement and Proliferation 
 The migration of white blood cells is an early and im-
portant event in the process of inflammation. Data from 
the late 1970s and 1980s show that tetracyclines are able to 
interfere with neutrophil function  [37] , especially with 
neutrophil movement, at least in vitro  [73] . Tetracyclines 
have also been found to be able to inhibit the mitogen-in-
duced proliferative responses of human lymphocytes in 
vitro by blockage of blast formation, with doxycycline be-
ing the most potent inhibitor among 3 tested tetracycline 
analogues  [37] . Gabler et al.  [74] could show that the chela-
tion of intracellular calcium, which, as a second messen-
ger, is important for the regulation of cell movement, is 
involved in the mechanism of inhibition. Besides migra-
tion, tetracyclines are also able to inhibit neutrophil-medi-
ated superoxide anion synthesis and degranulation, i.e. 
mechanisms which may also be involved in the inflamma-
tory process  [75] . Lately, Gabler and Tsukuda  [76] found 
that doxycycline also exerts a slight inhibitory effect on 
neutrophil adherence to surfaces coated with differing 
proteins, which interestingly could only be observed at low 
drug concentrations of doxycycline, while tetracycline in-
hibited leukocyte adherence in a dose-related manner.
 Inhibition of Granuloma Formation 
 Granulomatous inflammation is a common compo-
nent of many diseases, including rosacea. Tetracyclines 
have been shown to inhibit granuloma formation of hu-
man peripheral blood mononuclear cells incubated with 
dextrin beads  [77] . In this in vitro system doxycycline 
was proven to have a 10-fold stronger inhibitory activity 
than the parent drug tetracycline. Protein kinase C may 
be involved in the described mechanism of inhibition be-
cause tetracyclines caused a dose-dependent inhibition 
of protein kinase C in the same order of relative potency 
as was found for the inhibition of granuloma formation 
 [77] .
 Inhibition of ROS 
 Evidence has been accumulating that ROS released by 
inflammatory cells such as neutrophils  [12] are involved 
in the pathogenesis of rosacea. Patients with rosacea have 
higher ROS levels than healthy controls  [78] . Further-
more, markers of the antioxidant defense system are in-
versely correlated to the clinical manifestations of rosa-
cea. This means that in patients with mild rosacea (stage 
I or II) the superoxide dismutase activity was higher than 
in healthy controls while the malondialdehyde level (a 
biomarker for oxidative stress  [79] ) did not differ from 
controls, whereas in the severe involvement group (rosa-
cea stage III) the superoxide dismutase activity was lower 
than in the control group coupled to an increased level of 
malondialdehyde  [14] . These findings suggest that in 
mild rosacea the antioxidant defense system is activated 
in order to keep the ROS levels constant. In severer dis-
ease, the capacity of the antioxidant system is exhausted, 
leading to high levels of ROS. This belief is supported by 
recent data showing a higher ferritin expression in the 
skin, higher serum peroxide levels and significantly low-
ered total antioxidative potential serum levels in patients 
with rosacea compared with healthy control subjects, in-
dicating the onset of systemic oxidative stress in patients 
with rosacea  [80] . These findings support the ‘antioxi-
dant system defect hypothesis’ in rosacea patients, i.e. a 
reduced capacity to counter the negative effects of ROS, 
thus experiencing an increased inflammatory response 
 [13, 14] . This may also explain the pathogenetic associa-
tion between rosacea and photodamage, since long-term 
sun exposure is known to cause an increased generation 
of ROS, which, in turn, subsequently activate MMPs and 
in this way trigger the inflammation pathway  [13, 31] . 
 In vitro studies suggest that tetracyclines, especially 
doxycycline, show antioxidant effects by reducing ROS 
 [30, 60] . In vitro data propose that the antioxidant effect 
of these drugs does not originate from their capability to 
directly scavenge ROS but from their influence on white 
blood cells  [81] . However, the exact mechanism of action 
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of tetracyclines towards white blood cells, especially neu-
trophils, is still unknown  [12, 82] . The tetracycline-in-
duced reduction in ROS activity seems to be linked to a 
decreased degradation of extracellular matrix associated 
with a reduced activation of pro-MMPs  [31] . Thus, the 
antioxidant activity of tetracyclines may also benefit oth-
er mechanisms of inflammation.
 Inhibition of NO 
 The overproduction of NO has been implicated in the 
pathogenesis of various inflammatory diseases  [83] . NO 
secreted by endothelial cells and keratinocytes in re-
sponse to UVA and UVB radiation  [84] is thought to in-
cite the symptoms of rosacea as well  [13] . NO seems to be 
involved in vascular changes, i.e. vasodilation, which, in 
the case of rosacea, may contribute to increased vessel 
permeability, erythema, edema and telangiectatic symp-
toms  [13] . The increase in NO in response to UVA and 
UVB irradiation  [84] again refers to the widely accepted 
relationship between sun exposure and the pathogenesis 
of rosacea.
 Tetracyclines have been shown to inhibit the expres-
sion of nitric synthases under ex vivo conditions, with 
doxycycline being at least as effective as minocycline  [83] . 
Furthermore, doxycycline has been shown to be involved 
in the posttranscriptional regulation of inducible NO 
synthetase mRNA in murine macrophages  [85] . All these 
preliminary results suggest that tetracyclines, especially 
doxycycline, may have beneficial effects in the treatment 
of inflammatory diseases where excess NO has been im-
plicated in the pathophysiology, as also seems to be the 
case with rosacea.
 Inhibition of Angiogenesis 
 Angiogenesis seems to be involved in the pathogenesis 
of rosacea  [19, 86] and to be linked to MMP activity  [36] . 
In patients with rosacea, significantly increased dermal 
expression of the potent angiogenesis factor vascular en-
dothelial growth factor in lesional versus nonlesional 
skin (88.9 vs. 55.6%, respectively) was observed. Further-
more, more microvessels were observed in lesional com-
pared to clinically nonlesional skin, and a high microves-
sel density was found to be correlated with granuloma 
formation in the skin  [19] . There was also a correlation 
between high vascular density and the presence of ocular 
manifestations  [19] .
 Up to now, no study is available showing a direct or 
indirect antiangiogenic effect of tetracyclines in the 
pathogenesis of rosacea. Yet in a mouse model, doxycy-
cline has been found active in suppressing MMP-associ-
ated central nervous system angiogenesis  [49, 87] . In this 
model, doxycycline turned out to be a potent inhibitor of 
angiogenesis induced by vascular endothelial growth fac-
tor by decreasing the cerebral MMP-9 activity. The de-
crease in MMP-9 was associated with a reduced micro-
vessel count  [87] . More recently, it has been shown that 
doxycycline attains consistent antiangiogenic effects by 
inhibiting the migration of smooth-muscle cells playing 
an important role during angiogenesis and vascular re-
modeling  [88] . There is good evidence that inhibition of 
smooth-muscle cell migration is caused by the doxycy-
cline-induced upregulation of the MMP inhibitor tissue 
inhibitor of metalloproteinase-1  [88] .
 Influence on D. folliculorum 
 The saprophytic mite  D. folliculorum may play a patho-
genic role in papulopustular rosacea  [17–21] . Increased 
density of  D. folliculorum may be involved in the patho-
genesis of rosacea by supporting inflammation, mechan-
ical blockage of follicles or by acting as vectors for micro-
organisms  [17, 22] , while other authors favour the concept 
that increased mite density is the consequence of a previ-
ous treatment with topical steroids  [23] . Up to now, to our 
knowledge no study showing a relevant direct action of 
tetracyclines on the density of  D. folliculorum is avail-
able.
 Conclusion 
 It is highly probable that rosacea is of inflammatory 
nature. Inflammatory processes involved in the patho-
genesis of the disease concomitantly contribute to
the common symptoms such as inflammatory lesions in 
the stricter sense, erythema, telangiectasia, phymatous 
changes and ocular symptoms. Evidence has been accu-
mulating that tetracycline derivatives like doxycycline 
successfully used in the treatment of rosacea inhibit in-
flammatory pathways in skin diseases like acne and ro-
sacea by various modes of action. Although data for acne 
or rosacea are relatively scanty, the following modes of 
action of tetracyclines seem to be most relevant to an
effective treatment of these skin diseases: inhibition of 
MMPs, downmodulation of cytokines, inhibition of cell 
movement and proliferation, granuloma formation, ROS, 
NO and angiogenesis, whereas inhibition of PLA2 does 
not seem to matter greatly. The role of the saprophytic 
mite  D. folliculorum remains to be clarified. Neverthe-
less, future studies will have to show how tetracyclines 
work in rosacea treatment in detail.
 
 Tetracycline Actions Relevant to Rosacea 
Treatment  
Skin Pharmacol Physiol 2009;22:287–294 293
 References 
 1 Blount BW, Pelletier AP: Rosacea: a common 
yet commonly overlooked condition. Am 
Fam Physician 2002; 66: 435–440, 442. 
 2 Berg M, Liden S: An epidemiological study of 
rosacea. Acta Derm Venereol 1989; 69: 419–
423. 
 3 Kyriakis KP, Palamaras I, Terzoudi S, Em-
manuelides S, Michailides C, Pagana G: Epi-
demiologic aspects of rosacea. J Am Acad 
Dermatol 2005; 53: 918–919. 
 4 Eiseman AS: The ocular manifestations of 
atopic dermatitis and rosacea. Curr Allergy 
Asthma Rep 2006; 6: 292–298. 
 5 Dahl MV: Pathogenesis of rosacea. Adv Der-
matol 2001; 17: 29–45. 
 6 Rebora A: The management of rosacea. Am 
J Clin Dermatol 2002; 3: 489–496. 
 7 Brinnel H, Friedel J, Caputa M, Cabanac M, 
Grosshans E: Rosacea: disturbed defense 
against brain overheating. Arch Dermatol 
Res 1989; 281: 66–72. 
 8 Yale SH, Vasudeva S, Mazza JJ, Rolak L, Ar-
rowood J, Stichert S, Stratman ES: Disorders 
of f lushing. Compr Ther 2005; 31: 59–71. 
 9 Pelle MT, Crawford GH, James WD: Rosa-
cea. II. Therapy. J Am Acad Dermatol 2004; 
 51: 499–512. 
 10 Kang S, Cho S, Chung JH, Hammerberg C, 
Fisher GJ, Voorhees JJ: Inflammation and 
extracellular matrix degradation mediated 
by activated transcription factors nuclear 
factor-  B and activator protein-1 in inflam-
matory acne lesions in vivo. Am J Pathol 
2005; 166: 1691–1699. 
 11 Golub LM, Lee HM, Ryan ME, Giannobile 
WV, Payne J, Sorsa T: Tetracyclines inhibit 
connective tissue breakdown by multiple 
non-antimicrobial mechanisms. Adv Dent 
Res 1998; 12: 12–26. 
 12 Jones D: Reactive oxygen species and rosa-
cea. Cutis 2004; 74(suppl 3):17–20, 32–34. 
 13 Bikowski J: Examining inflammation as a 
common factor in theories of rosacea patho-
physiology. www.rosacea.org (last accessed 
November 24, 2008). 
 14 Oztas MO, Balk M, Ogüs E, Bozkurt M, 
Ogüs IH, Ozer N: The role of free oxygen 
radicals in the aetiopathogenesis of rosacea. 
Clin Exp Dermatol 2003; 28: 188–192. 
 15 Shanler SD, Ondo AL: Successful treatment 
of the erythema and flushing of rosacea us-
ing a topically applied selective   1-adrener-
gic receptor agonist, oxymetazoline. Arch 
Dermatol 2007; 143: 1369–1371. 
 16 Szlachic A: The link between  Helicobacter 
pylori infection and rosacea. J Am Acad Der-
matol Venereol 2002; 16: 328–333. 
 17 Bonnar A, Eusta P: The  Demodex mite popu-
lation in rosacea. J Am Acad Dermatol 1993; 
 28: 443–448. 
 18 Forton F, Seys B: Density of  Demodex follicu-
lorum in rosacea: a case-control study using 
standardized skin-surface biopsy. Br J Der-
matol 1993; 128: 650–659. 
 19 Aroni K, Tsagroni E, Kavantzas N, Patsouris 
E, Ioannidis E: A study of the pathogenesis 
of rosacea: how angiogenesis and mast cells 
may participate in a complex multifactorial 
process. Arch Dermatol Res 2008; 300: 125–
131. 
 20 Hsu CK, Hsu MML, Lee JYY: Demodicosis: 
a clinicopathological study. J Am Acad Der-
matol 2009; 60: 453–462. 
 21 Dhingra KK, Saroha V, Gupta P, Khurona N: 
 Demodex -associated dermatologic condi-
tions – a coincidence or an etiological cor-
relate: review with a report of a rare case of 
sebaceous adenoma. Pathology Res Pract 
2009; 205: 423–426. 
 22 Lacey N, Delaney S, Kavanagh K, Powell FC: 
Mite-related antigens stimulate inflamma-
tory cells in rosacea. Br J Dermatol 2007; 157: 
 474–478. 
 23 Dolenc-Voljč M, Pohar M, Lunder T: Density 
of  Demodex folliculorum in perioral derma-
titis. Acta Derm Venereol 2005; 85: 211–215. 
 24 Schauber J, Ruzicka T, Rupec RA: Cathelici-
din LL-37: ein zentraler Faktor in der Patho-
genese entzündlicher Dermatosen? Hautarzt 
2008; 59: 72–74. 
 25 Yamasaki K, Di Nardo A, Bardan A, Mu-
rakami M, Ohtake T, Coda A, Dorschner 
RA, Bonnart C, Descarques P, Hoynanian A, 
Morhenn VB, Gallo RL: Increased serine 
protease activity and cathelicidin promotes 
skin inflammation in rosacea. Nat Med 
2007; 13: 975–980. 
 26 Schauber J, Gallo RL: Antimicrobial pep-
tides and the skin immune defense system. 
Allergy Clin Immunol 2008; 122: 261–266. 
 27 Schmid-Wendtner MH, Korting HC: The pH 
of the skin surface and its impact on the bar-
rier function. Skin Pharmacol Physiol 2006; 
 19: 296–302. 
 28 Korting HC, Schöllmann C: Current topical 
and systemic approaches to treatment of ro-
sacea. J Eur Acad Dermatol Venereol 2009; 
 23: 876–882. 
 29 Thiboutot D, Thieroff-Ekerdt R, Graupe K: 
Efficacy and safety of azelaic acid (15%) gel 
as a new treatment for papulopustular rosa-
cea: results from two vehicle-controlled, 
randomized phase III studies. J Am Acad 
Dermatol 2003; 48: 836–845. 
 30 Sapadin AN, Fleischmajer R: Tetracyclines: 
nonantibiotic properties and their clinical 
implications. J Am Acad Dermatol 2006; 54: 
 258–265. 
 31 Del Rosso JQ, Webster GF, Kackson M, Ren-
don M, Rich P, Torok H, Bradshaw M: Two 
randomized phase III clinical trials evaluat-
ing anti-inflammatory dose doxycycline 
(40-mg doxycycline, USP capsules) adminis-
tered once daily for treatment of rosacea. J 
Am Acad Dermatol 2007; 56: 791–802. 
 32 Sneddon IB: A clinical trial of tetracycline in 
rosacea. Br J Dermatol 1966; 78: 649–652. 
 33 Baldwin HE: Systemic therapy of rosacea. 
Skin Therapy Lett 2007; 12: 1–5. 
 34 Del Rosso JQ: Medical treatment of rosacea 
with emphasis on topical therapies. Expert 
Opin Pharmacother 2004; 5: 5–13. 
 35 Bikowski JB, Goldman MP: Rosacea: where 
are we now? J Drugs Dermatol 2004; 3: 251–
261. 
 36 Bikowski JB: Subantimicrobial dose doxycy-
cline for acne and rosacea. Skinmed 2003; 2: 
 234–245. 
 37 Thong YH, Ferrante A: Inhibition of mito-
gen-induced human lymphocyte prolifera-
tive responses by tetracycline analogues. 
Clin Exp Immunol 1979; 35: 443–446. 
 38 Sandler C, Nurmi K, Lindstedt KA, Sorsa T, 
Golub LM, Kovanen PT, Eklund KK: Chem-
ically modified tetracyclines induce apopto-
sis in cultured mast cells. Int Immunophar-
macol 2005; 5: 1611–1621. 
 39 Onoda T, Ono T, Dhar DK, Yamanoi A, Na-
sague N: Tetracyline analogues (doxycycline 
and COL-3) induce caspase-dependent and 
-independent apoptosis in human colon can-
cer cells. Int J Cancer 2006; 118: 1309–1315. 
 40 Fainaru O, Adini I, Benny O, Bazinet L, 
Pravda E, D’Amato R, Folkman J: Doxycy-
cline induces membrane expression of VE-
cadherin on endothelial cells and prevents 
vascular permeability. FASEB J 2008; 22: 
 3728–3735. 
 41 Attur MG, Patel RN, Patel ND, Abramson 
SB, Amin AR: Tetracycline up-regulates 
COX-2 expression and prostaglandin E2 
production independent of its effect on nitric 
oxide. J Immunol 1999; 162: 3160–3167. 
 42 Samuelsson B, Morgenstern R, Jakobsson PJ: 
Membrane prostaglandin E synthase-1: a 
novel therapeutic target. Pharmacol Rev 
2007; 59: 207–224. 
 43 Maibach H: Second-generation tetracy-
clines, a dermatological overview: clinical 
uses and pharmacology. Cutis 1991; 48: 411–
417. 
 44 Berman B, Perez OA, Zell D: Update on ro-
sacea and anti-inflammatory-dose doxycy-
cline. Drugs Today (Barcelona) 2007; 43: 27–
34. 
 45 Theobald K, Bradshaw M, Leyden J: Anti-in-
flammatory dose doxycycline (40 mg con-
trolled-release) confers maximum anti-in-
flammatory efficacy in rosacea. Skinmed 
2007; 6: 221–226. 
 46 Walker C, Puumala S, Golub LM, Stoner JA, 
Reinhardt RA, Lee HM, Payne JB: Subanti-
microbial dose doxycycline effects on os-
teopenic bone loss: microbiologic results. J 
Periodontol 2007; 78: 1590–1601. 
 47 Golub LM, Ramamurthy N, McNamara TF, 
Gomes B, Wolff M, Casina A, Kapoor A, 
Zambon J, Ciancio S: Tetracyclines inhibit 
tissue collagenase activity: a new mechanism 
in the treatment of periodontal disease. J 
Periodont Res 1984; 19: 651–655. 
 48 Golub LM, Ramamurthy NS, McNamara TF, 
Greenwald RA, Rifkin BR: Tetracyclines
inhibit connective tissue breakdown: new 
therapeutic implications for an old family of 
drugs. Crit Rev Oral Biol Med 1991; 2: 297–
322. 
 Korting/Schöllmann Skin Pharmacol Physiol 2009;22:287–294294
 49 Webster G, Del Rosso JQ: Anti-inflamma-
tory activity of tetracyclines. Dermatol Clin 
2007; 25: 133–135. 
 50 Lalu MM, Cena J, Chowdhury R, Lam A, 
Schulz R: Matrix metalloproteinases con-
tribute to endotoxin- and interleukin-1  -in-
duced vascular dysfunction. Br J Pharmacol 
2006; 149: 31–42. 
 51 Vernillo AT, Ramamurthy NS, Golub LM, 
Rifkin BR: The nonantimicrobial properties 
of tetracycline for the treatment of periodon-
tal disease. Curr Opin Periodontal 1994; 2: 
 111–118. 
 52 Golub LM, Soumalainen K, Sorsa T: Host 
modulation with tetracyclines and their 
chemically modified analogues. Curr Opin 
Dent 1992; 2: 80–90. 
 53 Bonamigo RR, Bakos L, Edelweiss M, Cartell 
A: Could matrix metalloproteinase-9 be a 
link between  Demodex folliculorum and ro-
sacea? J Eur Acad Dermatol Venereol 2005; 
 19: 646–647. 
 54 Afonso AA, Sobrin L, Monroy DC, Selzer M, 
Lokeshwar B, Pflugfelder SC: Tear fluid ge-
latinase B activity correlates with IL-1  con-
centration and fluorescein clearance in ocu-
lar rosacea. Invest Ophthalmol Vis Sci 1999; 
 40: 2506–2512. 
 55 Uitto VJ, Firth JD, Nip L, Golub LM: Doxy-
cyline and chemically modified tetracyclines 
inhibit gelatinase A (MMP-2) gene expres-
sion in human skin keratinocytes. Ann NY 
Acad Sci 1994; 732: 140–151. 
 56 Choi DH, Moon IS, Choi BK, Paik JW, Kim 
YS, Choi SH, Kim CK: Effects of sub-antimi-
crobial dose doxycycline on crevicular f luid 
MMP-8, and gingival tissue MMP-9, TIMP-
1 and IL-6 levels in chronic periodontitis. J 
Periodont Res 2004; 39: 20–26. 
 57 Reddy MS, Geurs NC, Gunsolly JC: Peri-
odontal host modulation with antiprotein-
ase, anti-inflammatory, and bone-sparing 
agents: a systematic review. Ann Periodontol 
2003; 8: 12–37. 
 58 Buduneli E, Vardar-Sengül S, Buduneli N, 
Atilla G, Wahlgren J, Sorsa T: Matrix metal-
loproteinases, tissue inhibitor of matrix me-
talloproteinase-1, and laminin-5   2 chain 
immunolocalization in gingival tissue of
endotoxin-induced periodontitis in rats: ef-
fects of low-dose doxycycline and aledro-
nate. J Periodontol 2007; 78: 127–134. 
 59 Ciancio S, Ashley R: Safety and efficacy of 
sub-antimicrobial-dose doxycycline therapy 
in patients with adult periodontitis. Adv 
Dent Res 1998; 12: 27–31. 
 60 Golub LM, Lee HM, Stoner JA, Porsa T,
Reinhardt RA, Wolff MS, Ryan ME, Num-
mikoski PV, Payne JB: Subantimicrobial-
dose doxycycline modulates gingival crevic-
ular f luid biomarkers of periodontitis in 
postmenopausal osteopenic women. J Peri-
odontol 2008; 79: 1409–1418. 
 61 De Paiva CS, Corrales RM, Villareal AL, Far-
ley WJ, Li DQ, Stern ME, Pflugfelder SC: 
Corticosteroid and doxycycline suppress 
MMP-9 and inflammatory cytokine expres-
sion, MAPK activation in the corneal epithe-
lium in experimental dry eye. Exp Eye Res 
2006; 83: 526–535. 
 62 Kim HS, Luo L, Pflugfelder SC, Li DQ: Doxy-
cycline inhibits TGF-  -induced MMP-9 via 
SMAD and MAPK pathways in human cor-
neal epithelial cells. Invest Ophthalmol Vis 
Sci 2005; 46: 840–848. 
 63 Määtä M, Kari O, Tervahartiala T, Peltonen 
S, Kari M, Saari M, Sorsa T: Tear fluid levels 
of MMP-8 are elevated in ocular rosacea – 
treatment effect of oral doxycycline. Graefes 
Arch Clin Exp Ophthalmol 2006; 244: 957–
962. 
 64 Corbitt CA, Lin J, Lindsey ML: Mechanisms 
to inhibit matrix metalloproteinase activity: 
where are we in the development of clinical-
ly relevant inhibitors? Recent Pat Anticancer 
Drug Discov 2007; 2: 135–145. 
 65 Smith VA, Khan-Lim D, Anderson L, Cook 
SD, Dick AD: Does orally administered
doxycycline reach the tear film? Br J Oph-
thalmol 2008; 92: 856–859. 
 66 Pruzanski W, Greenwald RA, Street IO, La-
liberte F, Stefanski E, Vadas P: Inhibition
of enzymatic activity of phospholipase A2
by minocycline and doxycycline. Biochem 
Pharmacol 1992; 44: 1165–1170. 
 67 Mäkelä A, Kuusi T, Schröder T: Inhibition of 
serum phospholipase-A2 in acute pancreati-
tis by pharmacological agents in vitro. Scand 
J Clin Lab Invest 1997; 57: 401–407. 
 68 Kari O, Aho VV, Peltonen S, Kari M, Määtä 
M, Collan Y, Saari KM: Group IIA phospho-
lipase A 2 concentration of tears in patients 
with ocular rosacea. Acta Ophthalmol Scand 
2005; 83: 483–486. 
 69 Del Rosso JQ: A status report on the medical 
management of rosacea: focus on topical 
therapies. Cutis 2002; 70: 271–275. 
 70 Cazalis J, Bodet C, Gagnon G, Grenier D: 
Doxycycline reduces lipopolysaccharide-in-
duced inflammatory mediator secretion in 
macrophage and ex vivo human whole blood 
models. J Periodontol 2008; 79: 1762–1768. 
 71 Chung DR, Lee YS, Lee SS: Kinetics of in-
flammatory cytokines in patients with scrub 
typhus receiving doxycycline treatment. J 
Infect 2008; 56: 44–50. 
 72 Gürkan A, Cinarcik S, Hüseyinov A: Ad-
junctive subantimicrobial dose doxycycline: 
effect of clinical parameters and gingival 
crevicular f luid transforming growth factor-
  levels in severe, generalized chronic peri-
odontitis. J Clin Periodontol 2005; 32: 244–
253. 
 73 Esterly NB, Koransky JS, Furey NL, Trevisan 
M: Neutrophil chemotaxis in patients with 
acne receiving oral tetracycline therapy. 
Arch Dermatol 1984; 120: 1308–1313. 
 74 Gabler WL: Fluxes and accumulation of tet-
racyclines by human blood cells. Res Com-
mun Chem Pathol Pharmacol 1991; 72: 39–
51. 
 75 Gabler WL, Creamer HR: Suppression of hu-
man neutrophil functions by tetracyclines. J 
Periodont Res 1991; 26: 52–58. 
 76 Gabler WL, Tsukuda N: The influence of di-
valent cations and doxycycline on iodoacet-
amide-inhibitable leukocyte adherence. Res 
Commun Chem Pathol Pharmacol 1991; 74: 
 131–140. 
 77 Webster GF, Toso SM, Hegemann L: Inhibi-
tion of a model of in vitro granuloma forma-
tion by tetracyclines and ciprofloxacin:
involvement of protein kinase C. Arch Der-
matol 1994; 130: 748–752. 
 78 Bakar O, Demircay Z, Yuksel M, Haklar G, 
Sanisoglu Y: The effect of azithromycin on 
reactive oxygen species in rosacea. Clin Exp 
Dermatol 2007; 32: 197–200. 
 79 Nielsen F, Mikkelsen BB, Nielsen JB, Ander-
sen HR, Grandjean P: Plasma malondialde-
hyde as biomarker for oxidative stress: refer-
ence interval and effects of life-style factors. 
Clin Chem 1997; 43: 1209–1214. 
 80 Tisma VS, Basta-Juzbasic A, Jaganjac M, 
Brcic L, Dobric I, Lipozencic J, Tatzber F, 
Zarkovic N, Poljak-Blazi M: Oxidative stress 
and ferritin expression in the skin of patients 
with rosacea. J Am Acad Dermatol 2009; 60: 
 270–276. 
 81 Miyachi Y, Yoshioka A, Imamura S, Niwa Y: 
Effect of antibiotics on the generation of
reactive oxygen species. J Invest Dermatol 
1986; 86: 449–453. 
 82 Akamatsu H, Asada M, Komura J, Asada Y, 
Nowa Y: Effect of doxycycline on the genera-
tion of reactive oxygen species: a possible 
mechanism of action of acne therapy with 
doxycycline. Acta Derm Venereol 1992; 72: 
 178–179. 
 83 Amin AR, Attur MG, Thakker GD, Patel PD, 
Yvas PR, Patel RN, Patel IR, Abramson SB: A 
novel mechanism of action of tetracyclines: 
Proc Natl Acad Sci USA 1996; 93: 13014–
13019. 
 84 Roméro-Graillet C, Aberdam E, Clément M, 
Ortonne JP, Ballotti R: Nitric oxide produced 
by ultraviolet-irradiated keratinocytes stim-
ulates melanogenesis. J Clin Invest 1997; 99: 
 635–642. 
 85 Amin AR, Patel RN, Thakker GD, Lowen-
stein CJ, Attur MG, Abramson SB: Post-
transcriptional regulation of inducible nitric 
oxide synthase mRNA in murine macro-
phages by doxycycline and chemically mod-
ified tetracyclines. FEBS Lett 1997; 410: 259–
264. 
 86 Gomaa AH, Yaar M, Eyada MM, Bhawan J: 
Lymphangiogenesis and angiogenesis in 
non-phymatous rosacea. J Cutan Pathol 
2007; 34: 748–753. 
 87 Lee CZ, Xu B, McCulloch CE, Yang GY, 
Young WL: Doxycyline suppresses cerebral 
matrix metalloproteinase-9 and angiogensis 
induced by focal hyperstimulation of vascu-
lar endothelial growth factor in a mouse 
model. Stroke 2004; 35: 1715–1719. 
 88 Yao JS, Shen F, Young WL, Yang GY: Com-
parison of doxycyline and minocycline in 
the inhibition of VEGF-induced smooth 
muscle cell migration. Neurochem Int 2007; 
 590: 524–530. 
 
